- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03490786
A Dose Escalating Study to Assess the Safety and Tolerability of GT-001
March 30, 2018 updated by: Gila Therapeutics, Inc.
A Dose Escalating Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Lingual Application of GT-001 in Subjects With Obesity.
Dose escalation study of GT-001
Study Overview
Detailed Description
This is a dose-escalation design trial.
Twelve evaluable subjects (n=12) with BMIs of 30 to 40 kg/m2 will receive a single dose of placebo followed by study drug applied directly to the surface of the tongue mucosa with a disposable pipette followed by a one-day washout.
A total of seven (7) doses will escalate to a dose of 2.5 mg.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Tustin, California, United States, 92780
- Orange County Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult participants with obesity class I and II (BMI 30-40 kg/m2)
- Willing and able to provide written informed consent after reviewing the design and risks of the study and prior to completing any study-related procedure
- Willing and able to understand and comply with all study procedures and requirements.
- Women must have a predictable menstrual cycle and taking either monophasic oral contraceptives, or transdermal (Ortho Evra and Evra) at least one month prior to the study.
- Alternatively, post-menopausal women (defined as period of spontaneous amenorrhea for more than 1 year), and bilateral oophorectomized women are allowed into the study.
- Must be able to complete the Weight Efficacy Life-Style Questionnaire (WEL).
- Systolic blood pressure 100-160 mmHg at the time of screening.
- Stable and compliant treatment with oral medications for at least 4 weeks prior to screening.
- Women of child bearing potential (WOCBP) and males must agree to use at least two forms of contraception, of which one includes a barrier method (male condom) by the male partner, during study participation and continued for at least 90 days after the conclusion of the final dose.
- In addition, sperm donations by male subjects are not permitted during the subject's participation in the research study and for at least 90 days after the conclusion of the final dose. This criterion may be waived for male subjects who have undergone a vasectomy at least 6 months prior to screening.
- Willing and able to abstain from drugs, , and tobacco during study participation.
- Must have abstained from alcohol use for 48 hours prior to study day 1 through the duration of the study
- Must have abstained from any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study day 1.
- History of stable weight for at least 3 months prior to study entry.
Exclusion Criteria:
- Known hypersensitivity or allergy to Peptide YY, Pancreatic polypeptide (PP), other similar polypeptides or related compounds
- Known mutation to PYY or Y2 receptor gene (i.e., Pima Indians)
- Any medical condition for which modification of the medication that cannot be performed either safely or feasibly. Chronic diseases including metabolic, psychiatric, cardiovascular, endocrine, etc. for which the participant is not stable for 60 days prior to study initiation
- Female subjects who are pregnant or breast-feeding
- Female subjects of child bearing potential who are not on oral contraceptives or using biphasic or triphasic oral contraceptives
- Post-menopausal women who have not had a period of spontaneous amenorrhea for more than 1 year Unstable psychological or behavior profile (e.g., anxiety, depression)
- Subjects with fasting glucose levels greater than 125 mg/dl.
- Type I or Type II diabetes
- Poor dentition or oral pathology
- Unable or unwilling to give written informed consent.
- Temperature > 38°C (oral or equivalent)
- Sepsis or active infection requiring IV antimicrobial treatment
- Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns)
- Major neurologic event, including cerebrovascular events within 60 days prior to study initiation
- Significant pulmonary disease (e.g., history of oral daily steroid dependency, history of CO2 retention or need for intubation for acute exacerbation, or currently receiving IV steroids)
Known hepatic impairment as indicated by any of the following:
- Total bilirubin > 3 mg/dl
- Albumin < 2.8 mg/dl, with other signs or symptoms of hepatic dysfunction
- Increased ammonia levels, if performed, with other signs or symptoms of hepatic dysfunction
- Any organ transplant recipient or currently listed (anticipated in the next 60 days) for transplant
- Major surgery within 30 days prior to study initiation
- Positive screen for Hepatitis B (HbsAg, Hepatitis B Surface Antigen), Hepatitis C (anti-HCV, Hepatitis C Antibody), or HIV (anti-HIV 1/2)
- Received an investigational intervention within 30 days prior to study initiation, or have received PYY3-36, GLP-1 agonists, insulin or DPP-IV inhibitors in a previous clinical trial.
- Consumption of alcohol within 48 hours prior to study day1 and through study day 15 or early termination
- Use of any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months
- A positive urine drug screen for ethanol, cotinine, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and/or opiates
- A history of difficulty with donating blood, or having donated blood or blood products within 45 days prior to study initiation
- Use of weight loss drugs Orlistat (Alli or Xenical), Qsymia, Phentermine, Contrave, Lorcaserin, liraglutide, topiramate or exenatide within the last six months.
- Concurrent use of antihistamines
- Any condition that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study
- Unable to consume the test meal
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dose escalation
Single arm dose escalation.
|
PK, PD Study to Determine Safety of Escalating Doses of GT-001
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demonstrate safe doses of PGT-001 for reduction of body weight in obese volunteers.
Time Frame: approximately two weeks
|
Measures of the safety and tolerability of GT-001 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, and laboratory tests.
|
approximately two weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-relationship of adverse events
Time Frame: approximately two weeks
|
Incidence, severity and dose-relationship of adverse events as well as changes in physical examinations, vital signs and/or laboratory evaluations as a measure of safety and tolerability.
|
approximately two weeks
|
Dose relationship to peak plasma concentration of GT-001
Time Frame: Approximately two weeks
|
Peak plasma concentration of GT-001 to assess relationship to dose of GT-001.
|
Approximately two weeks
|
Dose relationship to hunger and satiety
Time Frame: approximately two weeks
|
Measurement of hunger and satiety will be conducted using visual analog scores to assess a relationship to dose of GT-001
|
approximately two weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 16, 2017
Primary Completion (ACTUAL)
August 9, 2017
Study Completion (ACTUAL)
October 2, 2017
Study Registration Dates
First Submitted
February 19, 2018
First Submitted That Met QC Criteria
March 30, 2018
First Posted (ACTUAL)
April 6, 2018
Study Record Updates
Last Update Posted (ACTUAL)
April 6, 2018
Last Update Submitted That Met QC Criteria
March 30, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001 (NavyGHB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Feeding and Eating Disorders
-
Meyer Children's Hospital IRCCSActive, not recruitingFeeding and Eating Disorders of ChildhoodItaly
-
Region of Southern DenmarkUniversity of Southern Denmark; JaschaFondenNot yet recruitingOther Specified Feeding or Eating Disorder | Eating Disorder NosDenmark
-
Benny Kerzner, MDAbbott NutritionWithdrawnFeeding and Eating Disorders of Childhood | Feeding DifficultiesUnited States
-
Kelly TannerCompleted
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; Filiere de Sante Maladies Rares TETECOURecruiting
-
Universidad Francisco de VitoriaDavid Varillas Delgado; María Cristina Martincrespo-Blanco; Saray Blanco-Abril; María Gema Cid-Expósito and other collaboratorsCompleted
-
Federal University of Health Science of Porto AlegreMinistry of Health, Brazil; Fundação de Amparo à Pesquisa do Estado do Rio...CompletedFeeding and Eating Disorders of ChildhoodBrazil
-
Emory UniversityCompletedFeeding and Eating Disorders of ChildhoodUnited States
-
Children's Mercy Hospital Kansas CityThe Gerber FoundationEnrolling by invitationFeeding and Eating Disorders of Childhood | Gastrostomy | Feeding Disorder of Infancy and ChildhoodUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH)RecruitingEating DisorderUnited States
Clinical Trials on GT-001
-
Swarthmore CollegeUniversity of PennsylvaniaUnknownDepression | AnxietyUnited States
-
Children's Mercy Hospital Kansas CityCompletedGastroesophageal Reflux | Family Satisfaction | Feeding DisorderUnited States
-
University of CalgaryCompletedSpinal Cord InjuriesCanada
-
Maharishi Markendeswar University (Deemed to be...Not yet recruiting
-
Ekso BionicsTerminatedSpinal Cord InjuriesUnited States
-
Stryker Trauma GmbHRecruitingFemoral FractureUnited States
-
Vrije Universiteit BrusselCompleted
-
Vrije Universiteit BrusselTerminated
-
Sun Yat-sen UniversityWest China Hospital; Chongqing Medical University; The Second Affiliated Hospital... and other collaboratorsRecruitingPrimary Angle Closure GlaucomaChina